Biodexa Pharmaceuticals plc American Depositary Shs

Biodexa Pharmaceuticals announced a 1-for-5 reverse ADR split, effective April 6, 2026, to bring its ADR price into compliance with Nasdaq's $1.00 minimum bid price requirement. The ratio change will convert every 5 old ADRs into 1 new ADR, with fractional shares sold and proceeds distributed to holders.

Biodexa Pharmaceuticals Plc reported updated data on a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma, with two out of four patients in the study now deceased.

Biodexa Pharmaceuticals Plc reported updated data on a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma, with two out of four patients in the study now deceased.

Ericsson reported better-than-expected Q2 sales and issued guidance, causing its shares to rise in pre-market trading. Several other stocks also saw significant pre-market movement, both positive and negative.

ConAgra Brands reported weaker-than-expected Q4 sales and issued FY25 EPS guidance below estimates, causing its shares to decline. Other notable movers include Kazia Therapeutics, Biodexa Pharmaceuticals, and Volcon, which saw significant gains, while Delta Air Lines, American Airlines, and United Airlines declined.